News

AstraZeneca’s Imfinzi (durvalumab) has been approved in the US for an additional dosing option, a 1,500mg fixed dose every four weeks, in the approved indications of unresectable Stage…
Read More...

Eli Lilly and Company and Incyte announced that the U.S. Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for the distribution and emergency use of…
Read More...

Zymeworks Inc. announced that the European Commission (EC) has granted Orphan Drug designation for zanidatamab, the company’s investigational HER2-targeted bispecific antibody, in…
Read More...

The U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to the oral investigational Bruton’s tyrosine kinase (BTK) inhibitor, rilzabrutinib, which has the…
Read More...

Pfizer Inc. and BioNTech SE announced that, after conducting the final efficacy analysis in their ongoing Phase 3 study, their mRNA-based COVID-19 vaccine candidate, BNT162b2, met all…
Read More...

Samsung Bioepis Co., Ltd. and Biogen Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application for SB11, a proposed…
Read More...

InMed Pharmaceuticals Inc. a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development…
Read More...

ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc, with Pfizer Inc. and Shionogi Limited as shareholders, announced that the US Food and Drug…
Read More...

Moderna, Inc. a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, announced that the…
Read More...

Cerebral Therapeutics, Inc., a clinical-stage pharmaceutical company developing innovative treatments for neurological diseases, announced that the first patient has been enrolled in a…
Read More...

Bristol Myers Squibb announced that it has successfully completed its acquisition of MyoKardia, Inc. in an all cash transaction for approximately $13.1 billion. With the completion of…
Read More...

Moderna, Inc. announced a supply agreement with the government of the United Kingdom to supply mRNA-1273, its COVID-19 vaccine candidate, beginning in March 2021 if it is approved for…
Read More...

Assembly Biosciences, Inc. and Door Pharmaceuticals, LLC announced that the companies have signed an exclusive, two-year collaboration and option agreement focused on the development of…
Read More...

Aeterna Zentaris Inc. a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests, today announced that, through a wholly-owned subsdiary, it…
Read More...

Merck known as MSD outside of the United States and Canada, announced a collaboration with the Bill & Melinda Gates Foundation (the foundation) where the foundation is committing to…
Read More...

Lead Pharma, a clinical stage pharmaceutical company, designing and developing innovative medicines for the treatment of immune mediated diseases and cancer, announced that it has…
Read More...

Olema Oncology, a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women's cancers, announced a clinical…
Read More...

The Phase 3 ENSEMBLE study of the single-dose regimen of JNJ-78436735, the investigational vaccine candidate for the prevention of COVID-19 being developed by the Janssen Pharmaceutical…
Read More...

Taiho Pharmaceutical Co., Ltd and Lung Therapeutics, Inc. announced an exclusive license agreement of LTI-01, a recombinant human single-chain urokinase plasminogen activator, currently…
Read More...

Jubilant Therapeutics Inc. a biopharmaceutical company advancing small molecule modulators to address unmet medical needs in oncology and autoimmune diseases, and OneThree Biotech, a…
Read More...